Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less

Executive Summary

CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.


Related Content

Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s ACA Repeal: What’s In It For Biopharma?
Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows
340B Impact: Roche Starts Educating Investors About Discount
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
Medicare Part B Demo Partially Shielded From Congress By CBO Scoring
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst